medigraphic.com
ISSN 1870-6592 (Print)
Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez

2012, Number 3

<< Back Next >>

Enf Neurol (Mex) 2012; 11 (3)

News in the pharmacological treatment of chronic heart failure

Ornelas GJA

Language: Spanish
References: 45
Page: 146-152
PDF size: 96.82 Kb.


ABSTRACT

Heart failure is currently one of the great epidemics of the century, that during the past two decades has increased dramatically and exponentially, ranking as the leading cause of morbidity and hospitalization worldwide up to 159% and ranking 10% morbidity of the Mexican population. That’s why today has changed dramatically the course of drug treatment, palliation aside from the complications of the disease evolution, toward identifying and breaking most accurate links in the chain of events adaptative physiological triggered by it, which in recent years has proven to be the direct cause of pathological progression of the disease and the exacerbation of a positive feedback system is magnified himself. Thus, in this review referred to the various compensatory mechanisms of heart failure, such as direct targets of current drug treatment, starting from the archives of the Spanish Journal of Cardiology and internal Medicine Mexican Magazine. With this new approach seeks to reduce mortality and hospitalization rates significantly, while improving the quality of life of people who have it.


REFERENCES

  1. Hunt SA, Abraham WT, Chin MH, Feldman AM et al. ACA/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult–summary article. J Am Coll Cardiol 2005; 46: 1116-43.

  2. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993; 22: 6A-13.

  3. Rodríguez AF, Banegas BJR, Guallar CP. Epidemiología de la insuficiencia cardiaca. Rev Esp Cardiol 2004; 57: 163-70.

  4. Manzano L, Sánchez MD, Rodríguez GP. La insuficiencia cardiaca en la práctica asistencial del internista. Rev Clin Esp 2005; 205 (7): 305-6.

  5. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 1998; 19: 990-1003.

  6. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006; 367: 356-67.

  7. Aldama LG, Piñeiro PM, Campo PEP. Insuficiencia cardiaca: Concepto, epidemiología, clasificación, etiología y fisiopatología. Medicine 2005; 9 (35): 2279-90.

  8. Cohn JN, Ferrari R, Sharpe NJ, on Behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35: 569-582.

  9. Szokodi I, Kinnunen P, Tavi P, Weckstrom M, Toth M, Ruskoaho H. Evidence for AMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation 1998 97: 1062-1070.

  10. Op. cit. 2004; 123 (4): 149-53.

  11. Kaluski E, Kobrin I, Zimlichman R, Marmor A et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: A prospective, multicenter, double blind, placebo-controlled study. J Am Coll Cardiol 2003; 41: 204-10.

  12. Pérez VF. Avances en el tratamiento de la insuficiencia cardiaca. Med Clin (Barc) 2004; 123 (4): 149-53.

  13. Mann DL. Inflammatory mediators and the failing heart. Past, present, and the foreseable future. Circ Res 2002; 91: 988-98.

  14. Goetze JP, Kastrup J, Rehfeld JF. The paradox of increased natriuretic hormones in congestive heart failure patients: Does the endocrine heart also fail in heart failure? Eur Heart J 2003; 24: 1471-2.

  15. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic Review BMJ 2005; 330: 625-33.

  16. Braunwald E, Bristow MR. Congestive heart failure: Fifty years of progress. Circulation 2000; 102: 14-23.

  17. Herrera-Garza EH, Stetson SJ, Cubillos-Garzon A, VooletichMT, Farmer JA, Torre-Amione G. Tumor necrosis factor-alpha: a mediator of disease progression in the failing human heart. Chest 1999; 115: 1170-1174.

  18. Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen AK et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83: 376-382.

  19. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-a. Circulation 1998; 97: 1375-1381.

  20. Bristow MR. Tumor necrosis factor-a and cardiomyopathy. Circulation 1998; 97: 1340-1341.

  21. Mann DL, Spinale FG. Activation of matrix metalloproteinases in the failing human heart: Breaking the tie that binds. Circulation 1998; 98: 1699-1702.

  22. Rao VU, Spinale FG. Controlling myocardial matrix remodeling: implications for heart failure. Cardiol Rev 1999; 7: 136-143.

  23. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006; 367: 356-67.

  24. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999; 34: 631-638.

  25. Drexler H. Hypertension, heart failure, and endothelial function. Am J Cardiol 1998; 82: 20S-22S.

  26. Op cit. Anderson TJ. 1999; 34: 631-638.

  27. Bauersachs J, Bouloumié A, Fraccarollo D, Hu K, Busse R, Ertl G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: Role of enhanced vascular superoxide production. Circulation 1999; 100: 292-298.

  28. Negrín JE, Cordiés L, Roselló N, Sánchez J, Negrín JA. Insuficiencia cardiaca crónica. Rev Cubana Med 2001; 40 (3): 195-211.

  29. Op cit. European Study Group. 1998; 19: 990-1003.

  30. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348 (20): 2007-18.

  31. Op cit. Hunt SA. Abraham WT, Chin MH, Feldman AM et al. ACA/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult–summary article. J Am Coll Cardiol. 2005; 46: 1116-43.

  32. Garrido BJP, Rodríguez FJA, García de LJ, Castro BA. Tratamiento de la insuficiencia cardiaca crónica. Medicine 2005; 9 (35): 2318-26.

  33. Pitt B, Zannad F, Remme WJ, Cody R et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.

  34. Pitt B, Poole-Wilson P, Segal R, Martínez FA et al. Effects of losartan vs captopril on mortality in patients with symptomatic heart failure: Rationale, design, and baseline characteristics.

  35. McMurray JJV, Pfeffer MA. Heart failure. Lancet 2005; 365: 1877-89.

  36. Garrido BJP, Rodríguez FJA, García de LJ, Castro BA. Tratamiento de la insuficiencia cardiaca crónica. Medicine 2005; 9 (35): 2318-26.

  37. Op cit. Hunt SA. 2005; 46: 1116-43.

  38. Op cit. J Am Coll Cardiol 2003; 41: 204-10.

  39. Mann DL. Inflammatory mediators and the failing heart. Past, present, and the foreseeable future. Circ Res 2002; 91: 988-98.

  40. Muñoz RN. Manejo del paciente con insuficiencia cardiaca aguda e insuficiencia cardiaca refractaria al tratamiento convencional. JANO 2005; 21 (1580): 49-55.

  41. Op cit. Garrido Bravo JP, Rodríguez FJA, García de LJ, Castro BA. Tratamiento de la insuficiencia cardiaca crónica. Medicine

  42. Mc Kelvie R. Cardiovascular disorders: Heart failure. Interventions. Clinical Evidence. BMJ Publishing Group Limited 2006. URL disponible en: http://www.clinicalevidence.com. Web publication date: 01/04/2006.

  43. Op cit. Garrido BJP. 2005; 9 (35): 2318-26.

  44. Pérez VF. Avances en el tratamiento de la insuficiencia cardiaca. Med Clin (Barc) 2004; 123 (4): 149-53.

  45. Cabrera A. Nuevas estrategias farmacológicas en la insuficiencia cardiaca 14/08/2007.




2020     |     www.medigraphic.com